- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07333105
Whole Body Vibration Versus Aerobic Training on Interleukin 6 and Endurance After Renal Transplantation
January 10, 2026 updated by: Zeinab Adel Mohamed, Cairo University
This study aimed to compare the effect of whole body vibration versus aerobic training on interleukin 6 and endurance after renal transplantation in patients after renal transplantation.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Even after a successful renal transplantation, the renal transplant recipients (RTRs) keeps on suffering the consequences of the uremic sickness such as increased cardiovascular risk, elevated level of inflammatory cytokines (IL6), decrease work capacity and quality of life.
Since biological and psychological problems are not completely solved by pharmacological treatment, physical training is able both, to improve graft function, work capacity and quality of life, and to reduce cardiovascular risk Therefore, this research aims to investigate effect of the whole-body vibration versus stationary bicycle as modes of aerobic exercises on interleukin 6 in patients and the 6-minutes walk test after renal transplantation, which may reduce the risks of cardiovascular disease, produce improvement of the biology of transplantation, increase of energetic metabolism, and allows for a better quality of life in these subtypes of patients.
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Cairo, Egypt
- Alkahraba Hospital in Cairo
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients of both sexes undergone renal transplantation.
- Their age will range from 30-45 years old.
- All patients will have the same medical and nursing care.
- All the patients will receive a good explanation of treatment and measurement device.
- They will be free from any genitourinary infections.
- They will be neurologically free.
Exclusion Criteria:
- Uncooperative patients
- Instability of patient's medical condition.
- Association of another medical problem as heart disease and respiratory problems.
- Diabetic patients.
- Patients who have history of medical chronic relevant diseases.
- Patients who have acute or chronic hepatitis.
- Patients have pacemaker.
- Patients who have genitourinary infections.
- Previous history of epilepsy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: whole body vibration
In this group of the study, thirty renal transplant recipients' patients will receive the whole-body vibration for, 20 minutes 3 times per week for 12 weeks after one month post renal transplantation
|
In a structured exercise session, subjects are instructed not to eat 2 hours prior and to wear comfortable clothing.
They will rest for 10-15 minutes before starting, and will be barefoot to allow for proper vibration effects from the force platform, which induces lateral body oscillations.
Before commencing, all parts of the whole-body vibration (WBV) device are checked for presence and functionality.
The initial phase includes a 5-10 minute warm-up of stretching and marching.
Over a 12-week period, subjects will undergo five 2-minute vibration treatments at 30 Hz, three times a week, followed by a 5-minute cool down.
Participants are to stand upright with slightly flexed knees, ensuring their body alignment is maintained.
Hand bars are available for those who feel insecure during the exercise.
|
|
Experimental: stationary bicycle
In this group, thirty renal transplant recipients' patients will receive aerobic exercise on stationary bicycle for 20 minutes 3 times per week for 12 weeks after one month post renal transplantation
|
Thirty patients will undergo a supervised exercise program on a stationary bicycle for 12 weeks, exercising three times weekly.
Each session will include a 5-minute warm-up (light walking), a 10-minute active phase (biking), and a 5-minute cool down (light walking).
The total duration will be 20 minutes, with exercise intensity set at 60-70% of maximum heart rate, calculated using the Karvonen formula (maximum heart rate=220-Age).
The walking speed will gradually increase from 60% to 70% of maximum heart rate over the course of the study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
measurement of Interleukin-6
Time Frame: at baseline and 12 weeks
|
Before starting the study, the following procedures will be performed.
The purpose of the study will be clearly explained to each patient using simple and understandable language, and a written informed consent form will be obtained from each participant as an agreement to be included in the study.
A venous blood sample (5 milliliters) will be collected from each subject in a sitting position under standardized conditions.
The collected samples will be transferred into sterilized tubes containing tripotassium ethylenediaminetetraacetic acid (K3-EDTA) and heparinized tubes, which will be placed on ice and then kept at room temperature.
Serum will be separated from plasma by centrifugation for 10 minutes.
Interleukin-6 (IL-6) levels will be measured using the enzyme-linked immunosorbent assay (ELISA) technique with commercially available ELISA kits based on the immunoturbidimetric method.
The normal reference range of interleukin-6 (IL-6) is 0-43.5 picograms per milliliter (pg/mL).
|
at baseline and 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
assessment of functional capacity
Time Frame: at baseline and 12 weeks
|
Subjects will be instructed to walk from end to end at the corridor of the hospital at their own pace, while attempting to cover as much distance as possible 6 min test will be evaluated before conduction of the training program and after the completion of the study Stop watch will be used for the 6-minute walk test, the test is timed with a stopwatch and the distance covered in 6 minutes walk test is used as a means to compare changes in performance capacity
|
at baseline and 12 weeks
|
|
assessment of endurance
Time Frame: at baseline and 12 weeks
|
The 30-Second Chair Stand Test (30CST) evaluates leg strength and endurance in older adults as part of the Fullerton functional fitness test battery, designed to address limitations of other sit-to-stand tests.
Conducted with a 17-inch folding chair, participants sit with feet shoulder-width apart and arms crossed.
After a demonstration, they attempt to complete as many stands as possible in 30 seconds, maintaining proper form.
Careful monitoring ensures only correctly executed stands are counted; the score reflects the total number completed, with results ranging from 0 to over 20, indicating varied fitness levels.
|
at baseline and 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2023
Primary Completion (Actual)
January 1, 2025
Study Completion (Actual)
March 1, 2025
Study Registration Dates
First Submitted
January 1, 2026
First Submitted That Met QC Criteria
January 9, 2026
First Posted (Estimated)
January 12, 2026
Study Record Updates
Last Update Posted (Actual)
January 13, 2026
Last Update Submitted That Met QC Criteria
January 10, 2026
Last Verified
January 1, 2026
More Information
Terms related to this study
Other Study ID Numbers
- Zeinab-phd
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Transplantation
-
Astellas Pharma IncAstellas Pharma Europe B.V.CompletedKidney Transplantation | Renal Transplantation | Transplantation, Kidney | Grafting, Kidney | Transplantation, RenalBelgium, Germany, Spain, Sweden, Italy, Switzerland, United Kingdom, Austria, France, Poland, Czech Republic, Netherlands
-
National Institute of Allergy and Infectious Diseases...Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN); PPD Development...CompletedKidney Transplantation | Renal Transplantation | Renal Transplant RecipientUnited States
-
Astellas Pharma Korea, Inc.CompletedKidney Transplantation | Renal Transplantation | Stable Renal RecipientsKorea, Republic of
-
University of Oslo School of PharmacyCompletedHeart Transplantation | Renal TransplantationNorway
-
NovartisCompletedOrgan Transplantation, Renal Transplantation
-
National Institute of Allergy and Infectious Diseases...Clinical Trials in Organ TransplantationTerminatedKidney Transplantation | Renal TransplantationUnited States
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedKidney Transplantation | Renal Transplant | Renal Transplantation | Transplant Rejection | Transplant ToleranceUnited States
-
University of North Carolina, Chapel HillMallinckrodtWithdrawnKidney Transplantation | Renal Transplantation | FSGSUnited States
-
Bristol-Myers SquibbCompletedKidney Transplantation | Graft Rejection | Renal TransplantationUnited States
-
Centre Hospitalier Universitaire de Saint EtienneMinistry of Health, FranceActive, not recruitingRenal TransplantationFrance
Clinical Trials on whole body vibration
-
Pamukkale UniversityNot yet recruitingPatellofemoral Pain, PFPTurkey (Türkiye)
-
Gazi UniversityGulhane Training and Research HospitalCompletedArthropathy of Knee | Whole-body Vibration | Swelling/ EdemaTurkey
-
The Hong Kong Polytechnic UniversityCompleted
-
The Hong Kong Polytechnic UniversityUnknown
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityCompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Chemotherapy-Induced Peripheral NeuropathyUnited States
-
University of the Balearic IslandsUnknown
-
Cairo UniversityRecruitingOverweight , ObesitySaudi Arabia
-
Cairo UniversityCompletedObesity | OverweightSaudi Arabia
-
Cairo UniversityNot yet recruitingQuality of Life | Balance | Chemotherapy Induced Peripheral Neuropathy (CIPN) | Fall Risk, Fall Prevention | Whole Body Vibration